Abstract
The feeding-related hormone, acyl-ghrelin, protects dopamine neurones in murine 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-based models of experimental Parkinson’s disease (PD). However, the potential protective effect of acyl-ghrelin on substantia nigra pars compacta (SNpc) dopaminergic neurones and consequent behavioural correlates in the more widely used 6-hydroxydopamine (6-OHDA) rat medial forebrain bundle (MFB) lesion model of PD are unknown. To address this question, acyl-ghrelin levels were raised directly by mini-pump infusion for 7 days prior to unilateral injection of 6-OHDA into the MFB with assessment of amphetamine-induced rotations on days 27 and 35, and immunohistochemical analysis of dopaminergic neurone survival. Whilst acyl-ghrelin treatment was insufficient to elevate food intake or body weight, it attenuated amphetamine-induced circling behaviour and SNpc dopamine neurone loss induced by 6-OHDA. These data support the notion that elevating circulating acyl-ghrelin may be a valuable approach to slow or impair progression of neurone loss in PD.
Graphical abstract
![](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10571-022-01282-9/MediaObjects/10571_2022_1282_Figa_HTML.png)
Avoid common mistakes on your manuscript.
Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disorder affecting an estimated 6.1 million people worldwide. The disease is characterised by age-related loss of dopamine-containing neurones in the substantia nigra pars compacta (SNpc) region of the adult brain. Alpha-synuclein immunopositive aggregates, termed Lewy bodies, are a neuropathological hallmark of PD that form in neurones (Irwin et al. 2013). This neuroanatomical pathology results in the loss of motor (bradykinesia, resting tremor) and non-motor (cognitive decline, sleep disturbance, constipation) function. Current therapies are available to control symptoms of disease, however, a large proportion of patients do not respond to treatment. In addition, the prolonged use of the dopamine replacement therapy, l-DOPA, often results in debilitating dyskinesias (Jenner 2008). Therefore, there is a major un-met clinical need for new protective and restorative treatments for PD.
Recently identified mutations in familial PD (LRRK2, GLB) and neurotoxins that induce Parkinsonian characteristics in animals converge on the cells’ energy producing organelles, the mitochondria. Parallel studies have identified a clear association between dopamine neurone dysfunction within the SNpc of PD brain and metabolic dysfunction (Burbulla et al. 2017). This knowledge has led to the search for molecules that improve mitochondrial function and biogenesis with the aim of enhancing cellular resilience to periods of bioenergetics stress. One such environmental factor that enhances both mitochondrial function and resilience against neurodegeneration is calorie restriction (CR; Morgan et al. 2018), but until recently, the underlying mechanism was not well understood. The stomach hormone, acyl-ghrelin, which is elevated by CR (Lutter et al. 2008) and increases mitochondrial activity in neurones (Andrews et al. 2008), is essential for mediating the beneficial effects of CR in the MPTP-model of PD (Bayliss et al. 2016). Acyl-ghrelin signalling induces phosphorylation of the cellular energy sensor, adenosine monophosphate-activated protein kinase (AMPK), to promote cell survival. The selective ablation of AMPK from dopaminergic neurones prevented acyl-ghrelin from protecting against MPTP-induced neurotoxicity. These findings are consistent with reports that treatment with exogenous acyl-ghrelin or synthetic ligands for the ghrelin receptor (GHS-R) protect against MPTP-induced SNpc lesions in mice (Andrews et al. 2009; Jiang et al. 2016) and the rat intra-striatal 6-OHDA model of PD (He et al. 2021). The major advantage of using this pre-clinical model is the quantifiable motor deficit induced by unilateral 6-OHDA lesion, and to the best of our knowledge, this is the first demonstration that acyl-ghrelin administration is efficacious in this rat model of PD.
Next, we performed histological analysis of dopamine (TH+) containing cells within the SNpc. The number of dopamine cells in the SNpc of the lesioned hemisphere was significantly reduced (58%) by 6-OHDA, relative to the non-lesioned hemisphere (P < 0.0001, Fig. 2E, F). In contrast, acyl-ghrelin pre-treatment attenuated this loss, resulting in the preservation of significantly more dopamine cells in the lesioned SNpc, relative to the 6-OHDA lesion group (P < 0.01, Fig. 2E, F). Indeed, there was no significant difference in the number of dopamine-containing cells in the SNpc of the acyl-ghrelin treated and sham groups (P > 0.05; Fig. 2E, F). Consistent with the expectation of this pre-clinical model, the number of dopamine cells in the SNpc was inversely correlated with amphetamine-induced ipsilateral rotations (Spearman r2 = 0.2442, P < 0.0001; Fig. 2G). Our results are consistent with previously published findings that acyl-ghrelin prevents dopamine cell loss in pre-clinical toxin-based models of PD (Andrews et al. 2009; Bayliss et al. 2016; Jiang et al. 2008; Moon et al. 2009) and extend the repertoire of pre-clinical models used to validate the therapeutic potential of acyl-ghrelin signalling in PD.
In support of our hypothesis that acyl-ghrelin signalling may be a valid therapeutic target for neuroprotection in PD, evidence from human PD patients suggests that post-prandial plasma total-ghrelin is reduced in PD individuals diagnosed with REM-sleep disorder, considered a pro-drome of PD (Unger et al. 2011). Furthermore, fasting levels of total- and acyl-ghrelin were reduced in male and female subjects diagnosed with PD (Song et al. 2017). Importantly, induced-pluripotent stem cell (iPSC)-derived dopaminergic neurones generated from patients carrying parkin gene (PARK2) mutations had significantly decreased GHS-R expression. Similarly, dopamine neurones of isogenic PARK2-iPSC lines mimicking PARK2 loss of function via CRISPR Cas9 technology also had reduced expression of GHS-R (Suda et al. 2018). More recently, we reported a reduction in the ratio of plasma acyl-ghrelin to unacyl-ghrelin specifically in individuals diagnosed with PD dementia when compared with cognitively intact PD and healthy control subjects (Hornsby et al. 2020). Given the limitations of administering putative therapeutic agents before the introduction of acute SNpc lesion, we suggest that studies using pre-clinical models linked with sporadic and familial PD are warranted to provide further insights into the role of ghrelin signalling in PD pathogenesis and progression. With growing interest in the role of systemic, particularly gastro-intestinal, factors in PD pathology (Arotcarena et al. 2020), our findings provide further evidence that the stomach hormone, acyl-ghrelin, protects dopamine neurones in a pre-clinical model of PD. Whilst the mechanism for the transport of acyl-ghrelin across the blood–brain barrier is not fully understood, the efficacy of acyl-ghrelin in promoting dopaminergic neurone survival and function in the absence of the widely reported metabolic effects of hyperghrelinaemia, suggest that human studies are warranted to test the efficacy of acyl-ghrelin peptide administration in slowing the progression of this debilitating disease.
Data availability
Enquiries about data availability should be directed to the authors.
References
Andrews ZB, Liu Z-W, Walllingford N, Erion DM, Borok E, Friedman JM, Tschöp MH, Shanabrough M, Cline G, Shulman GI, Coppola A, Gao X-B, Horvath TL, Diano S (2008) UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals. Nature 454(7206):846–851
Andrews ZB, Erion D, Beiler R, Liu Z-W, Abizaid A, Zigman J, Elsworth JD, Savitt JM, DiMarchi R, Tschop M, Roth RH, Gao X-B, Horvath TL (2009) Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci 29(45):14057–14065
Arotcarena ML, Dovero S, Prigent A, Bourdenx M, Camus S, Porras G, Thiolat ML, Tasselli M, Aubert P, Kruse N, Mollenhauer B, Damas IT, Estrada C, Garcia-Carrillo N, Vaikath NN, El-Agnaf OMA, Herrero MT, Vila M, Obeso JA et al (2020) Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 143(5):1462–1475
Bayliss JA, Lemus MB, Stark R, Santos VV, Thompson A, Rees DJ, Galic S, Elsworth JD, Kemp BE, Davies JS, Andrews ZB (2016) Ghrelin-AMPK signaling mediates the neuroprotective effects of calorie restriction in Parkinson’s disease. J Neurosci 36(10):3049–3063
Björklund A, Dunnett SB (2019) The amphetamine induced rotation test: a re-assessment of its use as a tool to monitor motor impairment and functional recovery in rodent models of Parkinson’s disease. J Parkinson’s Dis 9(1):17–29
Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, Savas JN, Kiskinis E, Zhuang X, Krüger R, Surmeier DJ, Krainc D (2017) Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science 1261(September):1255–1261
Dong J, Song N, **e J, Jiang H (2009) Ghrelin antagonized 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in MES23.5 Cells. J Mol Neurosci 37(2):182–189
He X, Yuan W, Liu F, Feng J, Guo Y (2021) Acylated ghrelin is protective against 6-OHDA-induced neurotoxicity by regulating autophagic flux. Front Pharmacol 11(January):1–12
Hornsby AKE, Buntwal L, Carisi MC, Santos VV, Johnston F, Roberts LD, Sassi M, Mequinion M, Stark R, Reichenbach A, Lockie SH, Siervo M, Howell O, Morgan AH, Wells T, Andrews ZB, Burn DJ, Davies JS (2020) Unacylated-ghrelin impairs hippocampal neurogenesis and memory in mice and is altered in Parkinson’s dementia in humans. Cell Rep Med 1(7):100120
Irwin DJ, Lee VM-YM-Y, Trojanowski JQ (2013) Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci 14(9):626–636
Jenner P (2008) Molecular mechanisms of l-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665–677
Jiang H, Li LJ, Wang J, **e JX (2008) Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. Exp Neurol 212(2):532–537
Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky SA, Anderson JG, Jung S, Birnbaum S, Yanagisawa M, Elmquist JK, Nestler EJ, Zigman JM (2008) The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 11(7):752–753
Moon M, Kim HG, Hwang L, Seo J-H, Kim S, Hwang S, Kim S, Lee D, Chung H, Oh MS, Lee K-T, Park S (2009) Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson’s disease by blocking microglial activation. Neurotox Res 15(4):332–347
Morgan AH, Rees DJ, Andrews ZB, Davies JS (2018) Ghrelin mediated neuroprotection—a possible therapy for Parkinson’s disease? Neuropharmacology 136:317–326
Song N, Wang W, Jia F, Du X, **e A, He Q, Shen X, Zhang J, Rogers JT, **e J, Jiang H (2017) Assessments of plasma ghrelin levels in the early stages of Parkinson’s disease. Mov Disord 32(10):1487–1491
Suda Y, Kuzumaki N, Sone T, Narita M, Tanaka K, Hamada Y, Iwasawa C, Shibasaki M, Maekawa A, Matsuo M, Akamatsu W, Hattori N, Okano H, Narita M (2018) Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson’s disease-like motor dysfunction. Mol Brain 11(1):1–9
Thompson NM, Gill DAS, Davies R, Loveridge N, Houston Pamela A., Robinson Iain C. A. F., Wells T (2004) Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145(1):234–242. https://doi.org/10.1210/en.2003-0899
Unger MM, Möller JC, Mankel K, Eggert KM, Bohne K, Bodden M, Stiasny-Kolster K, Kann PH, Mayer G, Tebbe JJ, Oertel WH (2011) Postprandial ghrelin response is reduced in patients with Parkinson’s disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson’s disease? J Neurol 258(6):982–990
Funding
This work was supported by funding from Parkinson's UK.
Author information
Authors and Affiliations
Contributions
DR, AJ, ML, GS, LR, LP, AM, TW and JD performed the studies. SD provided resources to complete the study. DR, ML, RB, TW and JD analysed the data. JD wrote the manuscript. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Rees, D., Beynon, A.L., Lelos, M.J. et al. Acyl-Ghrelin Attenuates Neurochemical and Motor Deficits in the 6-OHDA Model of Parkinson’s Disease. Cell Mol Neurobiol 43, 2377–2384 (2023). https://doi.org/10.1007/s10571-022-01282-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-022-01282-9